International Journal of Radiation Oncology * Biology * Physics
Volume 74, Issue 3 , Pages 747-752 , 1 July 2009

Salvage Treatment Improved Survival of Patients With Relapsed Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type

  • Xin-xing Zhang, M.D.

      Affiliations

    • Third Department of Oncology, West China Hospital, Sichuan University, Chengdu, People's Republic of China
    • ,
  • Cong-hua Xie, M.D.

      Affiliations

    • Department of Radiochemotherapy, Zhongnan Hospital, Wuhan University, Hubei, People's Republic of China
    • ,
  • Yong Xu, M.D.

      Affiliations

    • Third Department of Oncology, West China Hospital, Sichuan University, Chengdu, People's Republic of China
    • ,
  • Di Deng, M.D.

      Affiliations

    • Department of Radiochemotherapy, Zhongnan Hospital, Wuhan University, Hubei, People's Republic of China
    • ,
  • Yan-hai Zhao, M.D.

      Affiliations

    • Department of Radiotherapy, Renmin Hospital, Dongguan, Guangdong, People's Republic of China
    • ,
  • Bing-wen Zou, M.D.

      Affiliations

    • Third Department of Oncology, West China Hospital, Sichuan University, Chengdu, People's Republic of China
    • ,
  • Lin Zhou, M.D.

      Affiliations

    • Third Department of Oncology, West China Hospital, Sichuan University, Chengdu, People's Republic of China
    • ,
  • Mei Li, M.D.

      Affiliations

    • First Department of Oncology, West China Hospital, Sichuan University, Chengdu, People's Republic of China
    • ,
  • Jin Wang, M.D.

      Affiliations

    • Third Department of Oncology, West China Hospital, Sichuan University, Chengdu, People's Republic of China
    • ,
  • Wei-ping Liu, M.D.

      Affiliations

    • Department of Pathology, West China Hospital, Sichuan University, Chengdu, People's Republic of China
    • ,
  • Mei-juan Huang, M.D.

      Affiliations

    • Third Department of Oncology, West China Hospital, Sichuan University, Chengdu, People's Republic of China
    • State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, People's Republic of China
    • Corresponding Author InformationReprint requests to: Mei-juan Huang, M.D., Third Department of Oncology and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, People's Republic of China. Tel: (+86) 28-85422565/85423571; Fax: (+86) 28-85423571

Received 14 July 2008 ,Revised 22 August 2008 ,Accepted 26 August 2008.

References 

  1. Jaffe ES, Harris NL, Stein H, et al. World Health Organization classification of tumours Pathology and genetics of tumours of the hematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2001;p. 204–207
  2. Kim TM, Park YH, Lee SY, et al. Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage IE/IIE extranodal NK/T-cell lymphoma, nasal type. Blood. 2005;106:3785–3790
  3. Yong W, Zheng W, Zhang Y, et al. L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Int J Hematol. 2003;78:163–167
  4. Isobe K, Uno T, Tamaru J, et al. Extranodal natural killer/T-cell lymphoma, nasal type: The significance of radiotherapeutic parameters. Cancer. 2006;106:609–615
  5. Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: A prognostic model from a retrospective multicenter study. J Clin Oncol. 2006;24:612–618
  6. Cheung MM, Chan JK, Lau WH, et al. Early stage nasal NK/T-cell lymphoma: Clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys. 2002;54:182–190
  7. Tham IW, Lee KM, Yap SP, et al. Outcome of patients with nasal natural killer (NK)/T-cell lymphoma treated with radiotherapy, with or without chemotherapy. Head Neck. 2006;28:126–134
  8. Huang MJ, Jiang Y, Liu WP, et al. Early or upfront radiotherapy improved survival of localized extranodal NK/T lymphoma, nasal-type in the upper aerodigestive tract. Int J Radiat Oncol Biol Phys. 2008;70:166–174
  9. Chen AI, McMillan A, Negrin RS, et al. Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: The Stanford experience. Biol Blood Marrow Transplant. 2008;14:741–747
  10. Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol. 2006;24:181–189
  11. Koom WS, Chung EJ, Yang WI, et al. Angiocentric T-cell and NK/T-cell lymphomas: Radiotherapeutic viewpoints. Int J Radiat Oncol Biol Phys. 2004;59:1127–1137
  12. You JY, Chi KH, Yang MH, et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: A single institute survey in Taiwan. Ann Oncol. 2004;15:618–625
  13. Kristensen CA, Kjaer-Kristoffersen F, Sapru W, et al. Nasopharyngeal carcinoma. Treatment planning with IMRT and 3D conformal radiotherapy. Acta Oncol. 2007;46:214–220
  14. Allen AM, Tishler RB. Commentary: IMRT for head and neck cancer: Many chapters left to write. Oncologist. 2007;12:565–568
  15. Yamaguchi M, Kita K, Miwa H, et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer. 1995;76:2351–2356
  16. Fauci AS, Wolff SM. Radiation therapy of midline granuloma. Ann Intern Med. 1976;84:140–147
  17. Campo E, Cardesa A, Alos L, et al. Non-Hodgkin's lymphomas of nasal cavity and paranasal sinuses: An immunohistochemical study. Am J Clin Pathol. 1991;96:184–190
  18. Chaudhary PM, Mechetner EB, Roninson IB. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood. 1992;80:2735–2739
  19. Nagafuji K, Fujisaki T, Arima F, et al. L-asparagine induced durable remission of relapsed nasal NK/T-cell lymphoma after autologous peripheral blood stem cell transplantation. Int J Hematol. 2001;74:447–450
  20. Codegoni AM, Biondi A, Conter V, et al. Human monocytic leukemia expresses low levels of asparagine synthase and is potentially sensitive to L-asparaginase. Leukemia. 1995;9:360–361
  21. Sherf U, Ross DT, Waltthom M, et al. A gene expression data base for the molecular pharmacology of cancer. Nat Genet. 2000;24:236–244
  22. Yamaguchi M, Suzuki R, Kwong YL, et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci. 2008;99:1016–1020
  23. Drénou B, Lamy T, Amiot L, et al. CD3- CD56+ non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance. Blood. 1997;89:2966–2974
  24. Bekkenk MW, Jansen PM, Meijer CJLM, et al. CD56+ hematological neoplasms presenting in the skin: A retrospective analysis of 23 new cases and 130 cases from the literature. Ann Oncol. 2004;15:1097–1108

 X.-x.Z., C.-h.X., and Y.X. contributed equally to this work.

 Conflict of interest: none.

PII: S0360-3016(08)03534-7

doi: 10.1016/j.ijrobp.2008.08.066

International Journal of Radiation Oncology * Biology * Physics
Volume 74, Issue 3 , Pages 747-752 , 1 July 2009

Article Tools

* Image Usage & Resolution